Norgine's PLENVU® (NER1006) Receives Approval in Germany for Bowel Cleansing in Adults Prior to any Procedure Requiring a Clean Bowel
AMSTERDAM, February 8, 2018 /PRNewswire/ --
PLENVU®is the first 1-litre PEG bowel preparation
PLENVU®is superior to MOVIPREP® in providing high-quality cleansing in the colon ascendens- an important area for adenoma detection
Norgine B.V. today announced that the marketing authorisation for PLENVU® for bowel cleansing in adults prior to any procedure requiring a clean bowel, has been granted by the German regulatory authority. The approval was granted under the European decentralised procedure, with the UK as reference state. Norgine anticipates launch of PLENVU® in Germany later this year.
PLENVU® is now approved for use in Australia, Austria, Belgium, Croatia, Denmark, Finland, France, Hungary, Iceland, Ireland, Italy, Norway, Portugal, Romania, The Netherlands and in the UK (using the trademark PLEINVUEtm in Austria and The Netherlands).
PLENVU® is already commercially available in the UK and Belgium.
PLENVU® is a novel, low volume (1-litre) polyethylene glycol (PEG) 3350-based bowel preparation that has been developed by Norgine to provide whole bowel cleansing.
The approvals were based on data from the Phase III clinical trial programme, consisting of three multicentre, randomised, parallel group studies: MORA, NOCT and DAYB studies.
PLENVU® (NER1006) demonstrated an acceptable safety profile in the NOCT, MORA, and DAYB phase III studies.
Norgine manufactures PLENVU® and commercialises the product through its infrastructure in Europe and Australia and through its commercial partners in the rest of the world.
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...